Skip to main content

Advertisement

Table 3 Univariate analysis of clinicopathological prognostic factors (n = 178)

From: Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients

characteristics Hazard ratio 95% confidence interval p value*
disease-free survival (DFS)    
Age (>/< median) 0.912 0.509-1.633 n.s.
FIGO stage (III/IV vs. II vs. I) 2.112 1.486-3.002 < 0.001
Nodal involvement (N1 vs. N0) 3.125 1.750-5.579 < 0.001
Grading (G3 vs. G1/G2) 1.164 0.656-2.066 n.s.
histological type (adenomatous/adenosquamous vs. squamous) 1.118 0.597-2.093 n.s.
lymphatic invasion (L1 vs. L0) 2.934 1.300-6.621 0.010
depth of invasion (> 10 mm vs. 1-10 mm) 3.303 1.448-7.531 0.004
Adjuvant therapy (radiation vs. none) 1.834 0.961-3.499 0.066
Adjuvant therapy (chemoradiation vs.nNone) 0.743 0.325-1.699 n.s.
ALCAM IHC (positive vs. negative) 0.912 0.509-1.633 n.s.
cancer-specific survival (CSS)    
Age (>/< median) 1.011 0.472-1.638 n.s.
FIGO stage (III/IV vs. II vs. I) 2.265 1.555-3.299 < 0.001
Nodal involvement (N1 vs. N0) 3.664 1.972-6.811 < 0.001
Grading (G3 vs. G1/G2) 1.325 0.715-2.457 n.s.
histological type (adenomatous/adenosquamous vs. squamous) 1.012 0.507-2.020 n.s.
lymphatic invasion (L1 vs. L0) 2.960 1.232-7.113 0.015
depth of invasion (> 10 mm vs. 1-10 mm) 3.221 1.325-7.831 0.010
Adjuvant therapy (radiation vs. none) 1.840 0.930-3.643 0.080
Adjuvant therapy (chemoradiation vs. none) 0.674 0.266-1.713 n.s.
ALCAM IHC (positive vs. negative) 0.880 0.472-1.638 n.s.
  1. *significant p-values are shown in bold